Tissue Regenix Group Plc (LON:TRX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joined DirectorsTalk. Martin gives us a reminder of what Tissue Regenix does, discusses the poor operating performance, share prices, key messages from the report and thoughts on what will happen to the shares.
Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative products.
You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.
